Two years ago, Lake Worth Beach resident Jennifer Kirtley stepped on a scale and saw 328 pounds. After starting Wegovy, she says she has shed nearly 200 pounds, now slips into a size 6 and has watched the inflammation in a once‑arthritic knee mostly fade, giving her enough strength to make regular workouts part of her life.
Kirtley’s story is one many South Floridians are telling in exam rooms and waiting areas as prescriptions for GLP‑1 drugs climb and clinicians and researchers tally both the eye‑catching benefits and a new wave of safety questions. As reported by the Miami Herald, patients across the region say GLP‑1 medicines such as Ozempic, Wegovy, Mounjaro and Zepbound have helped with weight, pain and breathing, while fresh studies and regulatory moves are flagging risks that are harder to ignore.
What the research shows
A broad evidence mapping published in Nature Medicine pulled together data from hundreds of trials and large population cohorts. The review found potential upsides that stretch beyond the scale, including lower rates of some substance‑use and neurocognitive outcomes and improvements in cardiometabolic measures.
Those same authors, along with experts writing in outlets such as the BMJ, also stressed the fine print. The mapping highlighted increased risks for gastrointestinal problems and gallbladder disease and urged careful monitoring as GLP‑1 drugs move into new patient groups who may be older, sicker or using them primarily for weight loss.
Approvals and trials are expanding uses
Regulators have started to widen the official uses of these medications based on trial data. The FDA signed off on Eli Lilly’s Zepbound for moderate‑to‑severe obstructive sleep apnea in adults with obesity after results from the SURMOUNT‑OSA studies, according to an FDA news release.
The label for Novo Nordisk’s Wegovy was also updated to add an accelerated approval for treating metabolic dysfunction‑associated steatohepatitis (MASH), based on findings cited in the drug’s FDA prescribing information.
Risks clinicians are watching
Doctors say the upside can be substantial, but the tradeoffs are not theoretical. The growing literature and post‑marketing safety signals point to common gastrointestinal side effects such as nausea, vomiting and diarrhea, while observational studies have raised concerns about pancreatitis, gallbladder disease and other complications.
The Nature Medicine mapping and related reviews recommend that clinicians screen patients carefully, keep a close eye on warning signs, particularly in people with a history of pancreatic, gallbladder or eye disease, and have frank conversations about what could happen to weight and other health gains if a patient eventually stops the drug.
South Florida is feeling the effects
Across South Florida, clinics and telehealth outfits report that demand for brand‑name GLP‑1 medications is outstripping supply, and some patients pivot to compounded versions when insurance will not pick up the tab, a workaround that local reporting has treated with skepticism. CBS Miami examined clinics selling compounded semaglutide and urged patients to carefully vet telehealth and med‑spa operations that promise quick fixes.
At the same time, NBC Miami has tracked how cheaper pill formulations and discount programs are already reshaping who can actually get these drugs in 2026, with access shifting as prices, coverage rules and supply all move at once.
Doctors and researchers caution that GLP‑1s are powerful medical tools that call for close supervision, not casual experimenting. Patients in South Florida are being urged to sit down with their clinician to map out treatment goals, how side effects will be monitored and what realistic expectations look like for how long they may stay on a drug and what follow‑up will involve. The local story is not just rapid weight loss, it is a fast‑moving change in day‑to‑day care that is producing measurable health gains while raising serious safety and access questions that researchers and regulators are still trying to sort out.
.jpg){kind=link}